Background Gender differences in the chronotropic effects of infused isoprenaline have previously been described. The aim of the present study was to investigate possible gender differences in hypokalaemic, chronotropic, and electrocardiographic effects of inhaled terbutaline. Methods Twenty healthy volunteers (10 female) were recruited (mean age 24 years for women (F) and 22 years for men (M). Subjects were given either inhaled terbutaline 5 mg or placebo in single blind, randomised crossover fashion and the following measurements were made for four hours after inhalation: (a) serum potassium concentration; (b) heart rate; (c) electrocardiographic sequelae (T wave amplitude, Q-Tc interval). The effects of terbutaline on serum potassium was chosen as the primary end point for detecting a 0-3 mmol/l difference between sexes, with a Pl error of0l2 and a set at 0 05.
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Results The hypokalaemic effects ofterbutaline were significantly greater in women, the potassium results (means and 95% CI) being as follows: lowest potassium concentration-F 3-12 (2-96-3-28) mmol/l v M 3 65 (3-49-3-81) mmol/l; percentage change from baseline at one hour-F 15-4% (11-5-19-3%) v M 8-5% (4-6-12-3%); average potassium concentration during the four hours-F 3-39 (3-33-346) mmol/l v M 3-78 (3 72-3 85) mmol/l. There was no significant regression between body weight and the potassium response to terbutaline. There were also significant sex differences for T wave, Q-Tc, and heart rate response. The percentage fall in T wave amplitude 30 minutes after terbutaline was: F 44-6% (32-1-57 0%) v M 22-4% (9-9-34-8%). Male centrifuge within 10 minutes of colle immediately stored. Serum potassium was measured photometry (IL 943 analyser, Instrumentation Laboratory, Warrington) in batches after completion of the study. The within and between assay values for analytical imprecision (expressed as coefficients of variation, CV) were 0 7% and 1-8%. The normal reference range for our laboratory is 3 5-5 0 mmol/l. All ECG measurements were obtained from the mean of five complexes from standard lead II, with a paper speed of 50 mm/s and a gain of 0 5 mv/cm. Heart rate was assessed from the R-R interval. The heart rate corrected Q-T interval (Q-Tc) was calculated from the Bazett formula.14 Results POTASSIUM There were no significant gender differences in >= baseline potassium concentrations on the placebo day, although the concentration tended to be slightly lower in women: F 3-73 (3 60-3-86) mmol/l v M 3-83 (3 70-396) mmol/l. Serum potassium did not significantly change after inhalation of placebo in either sex.
Conclusions
Baseline potassium was lower in women before they inhaled terbutaline: F 3 69 (353- There were no gender differences in potassium responses three hours after terbutaline inhalation.
The average potassium concentrations throughout the four hours after terbutaline Female were significantly lower in women: minutes was F 44-6% (32-1-57T0%) v M 22-4% (9-9-3488%) (p < 0 01); (fig 2A) . T wave amplitude returned to baseline two hours after inhalation in the men whereas in the women T wave amplitude remained significantly blunted even at the end of the four hours (p < 0 01). The maximal fall in T wave amplitude was also greater in women ( fig 2B) . There was no significant regression (r =-023) between body weight and maximal individual response to terbutaline.
Six women showed ST depression after terbutaline compared with only one man. Five women also developed U waves after terbutaline compared with only one man. Terbutaline caused prolongation of Q-Tc, which was greater in the women. Average Q-Tc values were: F 424 (417-432) ms v M 403 (395-410) ms (p < 0 001). The Q-Tc interval remained significantly (p < 0 001) prolonged in the women for four hours after terbutaline but had returned to baseline by the same time in the men.
CHRONOTROPIC RESPONSE
The baseline heart rate was lower in women on both study days. There was no sex difference in the peak absolute heart rate achieved after they had inhaled terbutaline. This occurred 30 min- 
Discussion
This study was designed to investigate whether women showed greater sensitivity than men to the systemic adverse effects of inhaled terbutaline. Our data showed a clear sex difference in the hypokalaemic, chronotropic, and ECG responses to terbutaline. Both the nadir potassium concentration and the average potassium concentration over four hours were lower in women. The average potassium concentration over four hours represents the total hypokalaemic burden over this period and is probably the most clinically relevant variable in this respect. The maximal effect of terbutaline on ECG changes and potassium concentrations showed temporal correlation between the sexes, whereas recovery to normal of these variables did not. Both T wave and Q-Tc changes remained significantly different after four hours but potassium concentrations did not show any difference between the sexes after three hours, when data were expressed as percentage change from baseline.
What are the possible explanations of the gender differences in extrapulmonary f2 adrenoceptor responsiveness? Firstly, weight could conceivably have played a part. Our female volunteers were lighter in weight and therefore received a higher dose per unit body weight. We found no correlation, however, between absolute change in potassium concentration and body weight. This is supported by a previous study,'2 which showed that the greater chronotropic response to infused isoprenaline was also independent of body weight. Unfortunately, the plasma concentration of terbutaline was not measured and so we are unable to determine whether the greater pharmacodynamic response in women was due to a difference in the pharmacokinetics of the inhaled drug between the sexes. Conceivably the effects of body weight might assume greater importance during chronic dosing, once steady state concentrations have been achieved.
The hormone differences and particularly the presence of female steroid hormones might also play a part. We did not study our female volunteers at the same phase of their menstrual cycle and could not therefore eliminate this particular possibility. The oral contraceptive pill taken by some of the women could also explain the sex difference but, as with body weight, there was no pattern in the individual responses to suggest this. Equal numbers of women and men smoked and smoking could not therefore account for the difference in response. A more likely explanation is that the differences might be due to the effect of sex hormones on f2 adrenoceptors. This could be due to 
